Trials / Completed
CompletedNCT02509026
Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 210 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to study the benefits and risks of etanercept withdrawal in patients who have achieved a significant clinical response.
Detailed description
This multcenter, open-label, three period study will evaluate withdrawal and retreatment of etanercept in subjects with nr-ax SpA who achieved adequate response following 24 weeks of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Etanercept | 50 mg subcutaneous, once weekly, 24 weeks |
Timeline
- Start date
- 2015-09-24
- Primary completion
- 2019-05-28
- Completion
- 2019-09-06
- First posted
- 2015-07-27
- Last updated
- 2020-06-16
- Results posted
- 2020-06-16
Locations
82 sites across 14 countries: United States, Australia, Belgium, Colombia, Czechia, Finland, France, Germany, Hungary, Netherlands, Poland, Spain, Sweden, Taiwan
Source: ClinicalTrials.gov record NCT02509026. Inclusion in this directory is not an endorsement.